Evaluating as-needed inhaled corticosteroid strategies in asthma: expanding the benefits to mild asthma.

IF 2.9 3区 医学 Q2 RESPIRATORY SYSTEM
Expert Review of Respiratory Medicine Pub Date : 2023-07-01 Epub Date: 2023-08-21 DOI:10.1080/17476348.2023.2247973
Tommaso Bigoni, Franco Alfano, Federico Baraldi, Marco Contoli, Alberto Papi
{"title":"Evaluating as-needed inhaled corticosteroid strategies in asthma: expanding the benefits to mild asthma.","authors":"Tommaso Bigoni,&nbsp;Franco Alfano,&nbsp;Federico Baraldi,&nbsp;Marco Contoli,&nbsp;Alberto Papi","doi":"10.1080/17476348.2023.2247973","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Adherence to regular anti-inflammatory treatment is commonly low, and short-acting β2 agonist (SABA) overuse is common in patients with asthma, leading to an increased risk of asthma-related adverse events.</p><p><strong>Areas covered: </strong>Given the pivotal role of inflammation in asthma, multiple as-needed inhaled corticosteroid (ICS)-containing therapies have been developed, leading to a reduction in asthma exacerbations and improvement in symptom control. Currently, as-needed ICS/formoterol is one of the most commonly available formulations; however, other combinations such as ICS/SABA have been shown to be superior to as-needed SABA alone. Therefore, we performed a comprehensive review of the available scientific literature to enhance the advantages and disadvantages of each combination in clinical practice.</p><p><strong>Expert opinion: </strong>The future direction we foresee in asthma management consists in abandoning as-needed short-acting bronchodilators in favor of as-needed ICS-containing therapies. Each patient is unique and differs from others; consequently, a single option will not fit everyone. Patients' and physicians' awareness of this perspective can be reached through the development of multiple therapeutic options suitable for each condition that can be found in 'real life'.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":"17 8","pages":"623-634"},"PeriodicalIF":2.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Respiratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17476348.2023.2247973","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Adherence to regular anti-inflammatory treatment is commonly low, and short-acting β2 agonist (SABA) overuse is common in patients with asthma, leading to an increased risk of asthma-related adverse events.

Areas covered: Given the pivotal role of inflammation in asthma, multiple as-needed inhaled corticosteroid (ICS)-containing therapies have been developed, leading to a reduction in asthma exacerbations and improvement in symptom control. Currently, as-needed ICS/formoterol is one of the most commonly available formulations; however, other combinations such as ICS/SABA have been shown to be superior to as-needed SABA alone. Therefore, we performed a comprehensive review of the available scientific literature to enhance the advantages and disadvantages of each combination in clinical practice.

Expert opinion: The future direction we foresee in asthma management consists in abandoning as-needed short-acting bronchodilators in favor of as-needed ICS-containing therapies. Each patient is unique and differs from others; consequently, a single option will not fit everyone. Patients' and physicians' awareness of this perspective can be reached through the development of multiple therapeutic options suitable for each condition that can be found in 'real life'.

根据需要评估哮喘吸入皮质类固醇策略:将益处扩大到轻度哮喘。
引言:常规抗炎治疗的依从性通常较低,短效β2激动剂(SABA)过度使用在哮喘患者中很常见,导致哮喘相关不良事件的风险增加。所涵盖的领域:鉴于炎症在哮喘中的关键作用,已经开发出多种所需的含吸入皮质类固醇(ICS)的疗法,从而减少哮喘恶化并改善症状控制。目前,根据需要,ICS/福莫特罗是最常用的配方之一;然而,诸如ICS/SABA的其他组合已被证明优于单独的所需SABA。因此,我们对现有的科学文献进行了全面的审查,以增强每种组合在临床实践中的优势和劣势。专家意见:我们预计哮喘治疗的未来方向是放弃必要的短效支气管扩张剂,转而采用必要的含ICS的治疗方法。每个患者都是独一无二的,与其他患者不同;因此,单一的选择并不适合所有人。患者和医生对这一观点的认识可以通过开发适合“现实生活”中每种情况的多种治疗方案来实现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.80
自引率
2.60%
发文量
90
期刊介绍: Coverage will include the following key areas: - Prospects for new and emerging therapeutics - Epidemiology of disease - Preventive strategies - All aspects of COPD, from patient self-management to systemic effects of the disease and comorbidities - Improved diagnostic methods, including imaging techniques, biomarkers and physiological tests. - Advances in the treatment of respiratory infections and drug resistance issues - Occupational and environmental factors - Progress in smoking intervention and cessation methods - Disease and treatment issues for defined populations, such as children and the elderly - Respiratory intensive and critical care - Updates on the status and advances of specific disease areas, including asthma, HIV/AIDS-related disease, cystic fibrosis, COPD and sleep-disordered breathing morbidity
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信